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Abstract
Background: The use of small interfering RNAs (siRNAs) as genetic inhibitors of gene expression
has been shown to be an effective way of studying gene function in mammalian cells. Recently,
different DNA vectors for expression of small hairpin RNAs (shRNAs) or co-expression of sense
and antisense RNAs have been developed that direct siRNA-mediated gene silencing. One
expression cassette design that has been used to express long sense and antisense RNAs in non-
mammalian cell types is symmetric transcription using convergent promoters. However,
convergent transcription as a way to generate functional siRNAs in mammalian cells has not been
reported. This vector design permits the generation of expression constructs containing no repeat
sequences, but capable of inducing RNA interference (RNAi)-mediated gene silencing.
Results: With the aim of simplifying the construction of RNAi expression vectors, we report on
the production and application of a novel convergent promoter cassette capable of expressing
sense and antisense RNAs, that form double-stranded RNA, and mediate gene silencing in
mammalian cells. We use this cassette to inhibit the expression of both the EGFP transgene and
the endogenous TP53 gene. The gene silencing effect is Dicer-dependent and the level of gene
inactivation achieved is comparable to that produced with synthetic siRNA. Furthermore, this
expression system can be used for both short and long-term control of specific gene expression in
mammalian cells.
Conclusion: The experiments performed in this study demonstrate that convergent transcription
can be used in mammalian cells to invoke gene-specific silencing via RNAi. This method provides
an alternative to expression of shRNAs and co-expression of sense and antisense RNAs from
independent cassettes or a divergent promoter. The main advantage of the present vector design
is the potential to produce a functional siRNA expression cassette with no repeat sequences.
Furthermore, the cassette design reported is ideal for both routine use in controlling specific gene
expression and construction of randomised RNAi expression libraries for use in unbiased forward
genetic selections.
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Background
The introduction of double-stranded RNA (dsRNA) into a
range of organisms induces both a potent and specific
post-transcriptional gene silencing effect by directing deg-
radation of homologous target RNAs. This form of gene
suppression was first observed in Caenorhabditis elegans
and termed RNA interference or RNAi [1]. Biochemical
analysis of the mechanism of RNAi has indicated that the
mediators of gene silencing are 21 base pair small interfer-
ing RNAs (siRNAs) generated from longer dsRNA by the
RNAse III-like enzyme Dicer [2]. In mammalian cells, the
use of long dsRNA has been restricted due to the proposed
activation of an antiviral defense system that blocks pro-
tein translation leading to cell death [3]. Recently, this
limitation to the application of RNAi in mammalian cells
was overcome by the demonstration that chemically syn-
thesised 21 base pair siRNAs, the effectors of RNAi, could
be used in a wide range of human and mouse cell lines to
induce gene silencing [4–6]. This approach for transiently
controlling the expression of different target genes is fast
becoming the method of choice for determining gene
function in mammalian cells [7].
The transient nature of the gene silencing effect invoked
by siRNAs and the prohibitively high costs of chemical
synthesis have led to the development of DNA vectors
capable of expressing siRNAs intracellularly. Expression
cassettes have been developed using the endogenous U6
snRNA or H1 RNA polymerase III promoters to drive
expression of sequence-specific small hairpin RNAs (shR-
NAs) that stably regulate gene expression in mammalian
cells via RNAi [8–10]. As an alternative approach, some
groups have used the co-expression of sense and antisense
RNA strands from independent expression cassettes or a
divergent cassette [11,12]. The use of convergent tran-
scription from opposing promoters to induce RNAi-medi-
ated gene inhibition has been reported in trypanosomes
and Drosophila [13–15]. In these studies, a full-length
cDNA sequence is positioned between two identical pro-
moters such that independent transcription from each
promoter produces a pool of sense and antisense RNAs
capable of forming long dsRNA and undergoing process-
ing to the effector siRNAs. The utility of this approach for
inducing RNAi in mammalian cells has not been reported.
It has been predicted that the expression of up to 8% of
human genes may be influenced by antisense RNA or anti-
sense transcription [16–19]. This suggests that convergent
transcription does occur with a high frequency in the
human genome. However, this form of transcription may
regulate gene expression in cis by RNA polymerase colli-
sion or in trans via a RNAi-like mechanism [20]. In addi-
tion, to our knowledge, transcription in two directions
across a small region of DNA has not been demonstrated
to induce RNAi-mediated gene silencing in any organism.
In this study, we report on the construction of a conver-
gent promoter cassette capable of simultaneously express-
ing complementary sense and antisense RNAs that
mediate gene silencing in mammalian cells through the
RNAi pathway. We show that this vector design can be
used to inhibit transgene and endogenous gene expres-
sion in a Dicer-dependent manner and without activating
the dsRNA-dependent protein kinase PKR. This method of
expressing functional siRNAs in mammalian cells can be
used for both short and long-term regulation of specific
gene expression. We discuss the utility of this siRNA
expression vector format for routine regulation of specific
gene expression and the construction of genome-wide
RNAi libraries for forward genetic screening in mamma-
lian cells.
Results
Suppression of dEGFP transgene expression using a 
convergent transcription cassette
In previous reports it was shown that shRNAs generated
by transcription from a U6 snRNA promoter or short
sense and antisense RNAs expressed from separate U6
expression cassettes could generate gene silencing through
RNAi [8,9,21]. To develop a vector system for expressing
siRNAs in mammalian cells through convergent transcrip-
tion, we designed the convergent U6 promoter cassette
indicated in Figure 1A. To determine the intracellular effi-
cacy of this expression cassette for mediating specific gene
silencing, we used the EGFP gene as a target. We con-
structed a U6 convergent expression vector containing a
EGFP-specific insert (DualU6GFP) and co-transfected this
plasmid with the pEGFP-N1 plasmid and the lacZ expres-
sion vector pSVβ into EcR293 embryonic kidney cells.
Cells receiving DualU6GFP displayed a 40% reduction in
cell fluorescence compared with cells transfected with the
DualU6 control vector (data not shown).
To further examine the utility of the convergent U6 pro-
moters, and the mechanism by which this vector regulated
gene expression, we delivered the DualU6GFP plasmid to
EcR293 cells containing a stably integrated destabilised
EGFP (dEGFP) transgene [22]. As shown in figure 1B, cells
transfected with DualU6GFP displayed a reduction in
dEGFP-mediated cell fluorescence with the level of reduc-
tion in fluorescence equal to that of the synthetic EGFP
siRNA at 48 h post-transfection. Consistent with the
requirement for expression of the sense and antisense
RNAs from DualU6GFP, gene silencing via this vector dis-
played a 24 h delay compared with a synthetic siRNA tar-
geted to the same region of the dEGFP mRNA. The
reduction in cell fluorescence exhibited by cells contain-
ing the DualU6GFP plasmid was confirmed using fluores-
cence microscopy (Figure 1C). As with the synthetic
siRNAs, the residual population displaying cellBMC Biotechnology 2003, 3 http://www.biomedcentral.com/1472-6750/3/21
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fluorescence most likely represents cells that have not
been transfected with the expression plasmid.
It has been reported that shRNAs, or co-expression of
small complementary antisense and sense RNAs, produce
specific gene silencing by processing to siRNAs. To deter-
mine the mechanism of action of the DualU6GFP expres-
sion system, we examined transfected cells for dEGFP
protein levels, dEGFP mRNA levels and the presence or
absence of small RNAs encoded by the U6 convergent
expression vector containing an EGFP-specific insert.
Western analysis showed that the dEGFP protein levels
were reduced in cells expressing the siRNA from the U6
convergent expression vector and that this effect was spe-
cific (Figure 1D). The level of suppression of the dEGFP
protein was equivalent to that mediated by delivery of
synthetic siRNAs. An examination of dEGFP target mRNA
levels indicated that both the synthetic siRNAs and those
expressed from the U6 convergent plasmid reduced target
mRNA (Figure 1E). This latter result suggests that
DualU6GFP produces siRNAs capable of mediating turn-
over of the target mRNA, an observation consistent with
the mechanism of RNAi. To further confirm that the
DualU6GFP plasmid maintains the potential to produce
siRNAs, we identified the transcripts expressed from this
plasmid using northern blot analysis. As shown in figure
Strategy for generating intracellular siRNAs and effect of the expressed siRNAs on transgene expression Figure 1
Strategy for generating intracellular siRNAs and effect of the expressed siRNAs on transgene expression. (A) 
The convergent U6 expression cassette encodes sense (black) and antisense RNAs (red) that terminate at directional termina-
tion sequences (represented as five consecutive thymidines [T]). The complementary RNAs anneal and undergo further Dicer-
dependent processing to produce functional siRNAs. A U6 convergent expression vector containing an EGFP-specific insert 
(DualU6GFP) reduces dEGFP-mediated cell fluorescence as measured by (B) flow cytometry and (C) fluorescence microscopy. 
This same expression vector suppresses both (D) dEGFP protein levels and (E) dEGFP RNA levels. For Western analysis, β-
actin protein levels were used as a loading control. For RNA analysis, the control for loading was 18s rRNA.
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2A, bands of the expected length were observed only in
cells containing the DualU6GFP plasmid and not in vec-
tor controls. In addition, using strand-specific probes, we
were able to show that within the cells containing the U6
convergent EGFP vector both the antisense and sense
RNAs were present. The sizes of the transcripts confirmed
that the directional terminators were operative and that
U6-directed transcriptional machinery efficiently trun-
cated the antisense and sense transcripts within the con-
vergent transcription unit. The above results indicate that
the use of U6 convergent promoters in a single expression
cassette can produce complementary sense and antisense
RNAs that mediate specific gene suppression in a manner
consistent with RNAi.
Convergent promoters necessary for gene suppression
To demonstrate the necessity for convergent U6 promot-
ers in the DualU6GFP vector, and therefore the expression
of both sense and antisense RNAs, to mediate suppression
of the dEGFP target gene, we constructed derivatives of
this plasmid containing only a single U6 promoter. These
vectors were designated pU6GFPS and pU6GFPAs and
were expected to encode small sense and antisense EGFP
RNAs under control of the U6 promoter, respectively.
Each of these plasmids was used to transiently transfect
EcR293 cells expressing the dEGFP transgene. Cell popu-
lations were then analysed for dEGFP-mediated cell fluo-
rescence. This analysis indicated that the expression of
either sense or antisense EGFP strands alone was
Gene suppression by complementary RNAs expressed from a U6 convergent cassette is Dicer-dependent Figure 2
Gene suppression by complementary RNAs expressed from a U6 convergent cassette is Dicer-dependent. (A) 
The U6 convergent EGFP vector undergoes transcription in EcR293 cells to produce sense and antisense RNAs. (B) Suppres-
sion of target gene expression by the DualU6GFP vector requires the co-expression of both sense and antisense RNAs. (C) 
The DualU6GFP expression vector reduces dEGFP target gene expression in a Dicer-dependent manner. (D) Co-expression 
of complementary RNAs from the U6 convergent expression cassette does not activate PKR. Hela cells were treated with 0.1 
µM calyculin A and serve as a positive control for activated PKR.
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insufficient to suppress the dEGFP gene, and that full inhi-
bition of this target gene required the co-expression of
both strands within the same cell (Figure 2B).
Convergent transcription induces RNAi
Given that the cells co-expressing the sense and antisense
EGFP RNAs displayed many of the hallmarks of RNAi, we
were interested in determining whether gene silencing
occurred through formation of dsRNA. Toward this end,
we utilised the Dicer siRNA as a tool to determine if the
observed suppression was Dicer-dependent [23–25]. In
this experiment, EcR293 cells expressing the dEGFP trans-
gene were transfected with DualU6GFP in the presence
and absence of the synthetic siRNA specific for Dicer. As
shown in Figure 2C, the Dicer siRNA completely reversed
the reduction in cell fluorescence mediated by the EGFP-
specific U6 convergent plasmid. In contrast, cells trans-
fected with both the synthetic EGFP- and Dicer-specific
siRNAs still displayed a reduction of cell fluorescence, as
the mechanism of synthetic siRNAs is Dicer-independent.
These results suggest that the small sense and antisense
RNAs encoded by DualU6GFP anneal to form dsRNA that
is processed by Dicer into authentic siRNAs. It is most
likely that gene silencing is then directed by these proc-
essed siRNAs.
It has been proposed that dsRNA greater than 30 base
pairs in size induce a global response that results in acti-
vation of the double-stranded RNA-specific protein kinase
PKR [3]. To eliminate PKR activation as being responsible
for the gene silencing observed using this unique expres-
sion system, we examined the levels of both total PKR and
activated PKR in EcR293 cells receiving the DualU6GFP
plasmid. This analysis indicated that co-expression of the
sense and antisense EGFP RNAs and formation of dsRNAs
did not activate PKR (Figure 2D), suggesting that the
observed gene silencing effect was specific and not related
to this global response mechanism.
Stable gene regulation using a convergent promoter 
system
To examine the utility of the DualU6GFP expression sys-
tem in long-term regulation of gene expression in mam-
malian cells, either the DualU6GFP plasmid, or the
control vector, was co-delivered with pREP7 (containing
the marker conferring resistance to hygromycin) to
EcR293 cells expressing the dEGFP transgene. Following
selection for cells stably maintaining the DualU6GFP
plasmid, cells were examined for dEGFP-mediated cell
fluorescence. This analysis demonstrated that cells con-
taining the DualU6GFP plasmid displayed a significant
(80%) reduction in cell fluorescence compared with cells
receiving the control vector (Figure 3). This result indi-
cates that the convergent expression cassette described can
be used to mediate long-term regulation of gene expres-
sion in mammalian cells.
Convergent transcription regulates an endogenous gene
We next determined whether the U6 convergent promoter
system could be used to control the expression of endog-
enous genes in mammalian cells. For this purpose, we
chose as a target the TP53 gene that encodes the p53
tumor suppressor protein. To this end, we constructed a
U6 convergent expression vector containing an insert
encoding a p53-specific siRNA. The target site selected was
identical to that reported earlier for synthetic p53-specific
siRNAs [26]. The p53-specific U6 convergent expression
plasmid, DualU6p53, was transfected into MDA MB 231
breast cancer cells and, at 48 h and 120 h post-transfec-
tion, cells were harvested and analysed for p53 protein
levels. As shown in Figure 4A, delivery of the DualU6p53
plasmid into MDA MB 231 cells resulted in a significant
and specific reduction of p53 protein, especially at 120 h.
This result indicates that the U6 convergent promoter sys-
tem can be used to effectively suppress the expression of
endogenous genes through RNAi in mammalian cells.
Convergent transcription induces longer-term suppression 
of p53
To demonstrate the effectiveness of convergent transcrip-
tion in mediating longer-term control of p53 gene
Stable suppression of dEGFP-mediated cell fluorescence Figure 3
Stable suppression of dEGFP-mediated cell fluores-
cence. EcR293 cells containing a stable integrated dEGFP 
transgene were co-transfected with DualU6GFP and pREP7 
and selected in 500 ug/ml hygromycin for two weeks. Cell 
fluorescence is reduced in stable pools of cells containing the 
DualU6GFP vector compared with those receiving the con-
trol DualU6 vector.
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expression, we co-delivered the DualU6p53 plasmid with
pREP7 (containing the hygromycin resistance gene) to
EcR293 cells containing the dEGFP transgene. In addition,
we also co-transfected these same cells with the
DualU6GFP and pREP7. Each of these populations, and
the vector alone with pREP7, were exposed to hygromycin
selection for two weeks. Stable cells were selected and
examined for p53 protein levels by Western blotting. This
analysis indicated that cells containing the DualU6p53
plasmid showed a significant reduction in p53 protein
levels compared with cells receiving the control vector or
cells containing DualU6GFP (Figure 4B). This suggests
that the observed suppression is sequence-specific and
that long term regulation of endogenous gene expression
can be achieved in mammalian cells using convergent
transcription.
Discussion
In this report, we use convergent RNA polymerase III pro-
moters to direct transcription of target gene-specific sense
and antisense RNAs. This strategy has been used in trypa-
nasomes and Drosophila for generating long dsRNA and
inducing RNAi-mediated gene suppression [13–15].
However, the suitability of this vector design has not been
tested in mammalian cells. The testing of convergent pro-
moters to invoke RNAi requires consideration of features
unique to RNAi-directed gene silencing in these cells.
Firstly, it is possible that convergent transcription may not
generate complementary RNAs, but instead truncated
transcripts lacking homology due to collision between
RNA polymerases [19]. Alternatively, transcription from
opposing promoters may produce sense or antisense
RNAs, but not both, due to domination by one promoter.
Secondly, unlike most other organisms, the length of the
complementary RNAs must be below 30 bp in size as
longer dsRNAs have been reported to activate dsRNA-
dependent protein kinase PKR and non-specific RNases.
Finally, the efficiency of convergent transcription across a
DNA insert of such limited size within mammalian cells is
unknown and may impact on the synthesis of the comple-
mentary RNAs [17].
To examine this vector design we constructed and tested
an expression cassette containing convergent U6 snRNA
promoters flanking DNA inserts specific for a region of the
cellular mRNA of interest. Data presented in this report
indicates that convergent transcription of a short region of
DNA specific to a target gene can be used to suppress its
expression in mammalian cells. The gene silencing effect
mediated by co-expression of sense and antisense RNAs
was shown to be dependent on the level of Dicer, suggest-
ing that these complementary RNAs form a dsRNA inter-
Suppression of p53 protein levels using a convergent U6 expression vector Figure 4
Suppression of p53 protein levels using a convergent U6 expression vector. (A) Transient suppression of p53 pro-
tein levels. Plasmids DualU6 and DualU6p53 or p53-specific siRNAs 1 and 2 were transfected into MDA MB 231 cells and, at 
48 h and 120 h post-transfection, p53 and β-actin protein levels were determined using Western analysis. (B) Long term sup-
pression of p53 protein levels. EcR293 cells containing a stably integrated dEGFP transgene were co-transfected with DualU6, 
DualU6GFP or DualU6p53 and pREP7. Following selection in hygromycin, cell populations were analysed for p53 and β-actin 
protein levels.
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mediate that is processed by Dicer to functional siRNAs.
Furthermore, the level of suppression observed using
convergent transcription was comparable to that medi-
ated by synthetic siRNAs directed against the same target
site. This vector design was shown to confer both transient
and long-term regulation of target gene expression with-
out activating the antiviral global response.
All DNA vectors used to express shRNAs or co-express
sense and antisense RNAs in mammalian cells to induce
RNAi contain repeated sequences specific to the gene of
interest [8,9,12]. The presence of inverted repeats has
been reported to affect the stability of these vectors and
may possibly impact on the longer-term regulation by
RNAi. This situation is further complicated when the
inverted repeat sequences are contained within retroviral
vectors [27–30]. In this paper, we use two opposing U6
promoters for testing the utility of symmetrical transcrip-
tion as a method of inducing RNAi in mammalian cells.
This design eliminates the presence of repeat sequences
derived from the target gene. Replacement of one U6 pro-
moter with an H1 promoter would produce a siRNA
expression cassette lacking repeat sequences. This design
is expected to increase both the cloning efficiency and the
stability of RNAi expression vectors.
The system described in this report provides a novel alter-
native expression modality to shRNA-expressing plasmids
for gene silencing in mammalian cells. This opposing pro-
moter system forms the basis for generating randomised
RNAi libraries in which random double-stranded DNA
oligonucleotides can be introduced between the conver-
gent U6 promoters. The expansion of this design to
include two different RNA polymerse III promoters in
opposing orientations, with random oligonucleotide
sequences between the convergent promoters, would pro-
duce a randomised RNAi library expressing functional siR-
NAs in mammalian cells and containing no inverted
repeat sequences. Such genome-wide RNAi libraries
would be useful for performing forward genetic screens
similar to those reported using randomised ribozyme
libraries [31–33] and universal peptide libraries [34]. A
significant advantage in using randomised RNAi libraries,
over other nucleic acid-based libraries, in forward genetic
approaches in mammalian cells would be the
identification of 21 bases of complete sequence comple-
mentarity to the intracellular target RNA that is linked to
the modified cellular phenotype. This length of sequence
conservation could be used to more effectively identify
candidate genes using homology-based search tools. In
addition, these sequences could be chemically synthe-
sised and used as tools for further validation of the iden-
tified targets or as potential therapeutics.
Conclusions
The present study introduces a novel method for express-
ing functional siRNAs capable of directing specific gene
silencing in mammalian cells through RNAi. The vector
design provides a feasible alternative to other DNA vectors
used for expressing siRNAs, with the added benefit of
eliminating the incorporation of inverted repeat
sequences. As highlighted above, this DNA vector has a
number of advantages for the generation of randomised
RNAi expression libraries suitable for genome-wide
somatic cell genetics.
Methods
Constructs and siRNAs
To construct DualU6 containing convergent U6 promot-
ers, the primers 5'-GCG CAA GCT TAT AGG GAA TTC
GAG CTC GGT A-3', and 5'-GCG CTC TAG AGG TGT TTC
GTC CTT TCC ACA A-3' were used to PCR amplify the
U6+1 promoter region from pTZ(U6+1) [9] and the
resulting amplicon cloned as a XbaI-HindIII fragment
into pTZ(U6+1). The inserts encoding the sense and anti-
sense RNAs were designed to include target-specific
sequences (in bold below) flanked by two directional
transcription terminators composed of five thymidines.
The oligonucleotides used to construct DualU6GFP were
5'-TCG ACA AAA ACG GCA AGC TGA CCC TGA AGT TTT
T-3' and 5'-CTA GAA AAA CTT CAG GGT CAG CTT GCC
GTT TTT G-3', while the following were used to construct
DualU6p53: 5'-TCG ACA AAA AGA CTC CAG TGG TAA
TCT ACT TTT T-3' and 5'-CTA GAA AAA GTA GAT TAC
CAC TGG AGT CTT TTT G-3'. These oligonucleotides were
synthesised (Sigma Genosys, Sydney, Australia), annealed
and cloned into the SalI and XbaI sites of DualU6. The
control vectors pU6GFPS and pU6GFPAs were con-
structed by deleting a single U6 promoter from
DualU6GFP by HindIII-XbaI and HincII-AflIII double
digests, respectively.
In transient transfection experiments aimed at testing the
DualU6GFP, the target plasmid used was pEGFP-N1
which contains the EGFP reporter under control of the
CMV immediate early promoter (Clontech, Palo Alto,
CA). The vector pSVβ, encoding the β-galactosidase pro-
tein, was co-transfected with the EGFP siRNA and the
pEGFP-N1 plasmid to act as a transfection control. The β-
galactosidase activity was assayed using the β-galactosi-
dase enzyme assay system according to the manufacturer's
instructions (Promega, Madison, WI).
In the production of stable pooled populations contain-
ing the DualU6 vector control or DualU6GFP, each plas-
mid was co-transfected into EcR293 cells (containing an
integrated dEGFP transgene) in a 10:1 molar ratio with
the episomal plasmid pREP7 (Invitrogen, Carlsbad, CA).BMC Biotechnology 2003, 3 http://www.biomedcentral.com/1472-6750/3/21
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This plasmid contains a positive selectable marker confer-
ring resistance to hygromycin.
The RNA oligonucleotides used to form the siRNAs were
synthesised by Dharmacon Research Inc (CO, USA) and
the sequences were: GFP, 5'-CGG CAA GCU GAC CCU
GAA G dTdT (sense); p53(siRNA1), 5'-GAC UCC AGU
GGU AAU CUA C dTdT (sense); and p53(siRNA2), 5'-
GCA UGA ACC GGA GGC CCA U dTdT (sense). The
sequence of the Dicer-specific siRNA used was as reported
in [24]. All RNA oligonucleotides were annealed with
their corresponding antisense strands as described [4].
Cell culture and transfection
Mammalian cells used in this study included the human
embryonic kidney (HEK) cell line EcR293 (Invitrogen,
CA, USA) and the human breast cancer cell line MDA MB
231. The construction of the EcR293 cell line expressing
the dEGFP gene has been described [22]. EcR293 cells and
their derivatives were maintained in DMEM containing
10% fetal calf serum supplemented with glutamine, strep-
tomycin and penicillin. MDA MB 231 cells were grown in
RPMI containing 10% fetal calf serum supplemented with
glutamine.
Cells were seeded into six well plates 24 h prior to trans-
fection. For all transfections, a total of 4 µg of plasmid
DNA or 60 nM of siRNA was delivered using Lipo-
fectamine 2000 (Invitrogen, CA, USA)) according to the
manufacturer's instructions. Cells were harvested at 24 h
and 48 h for flow cytometry analysis of EGFP expression
(Becton Dickinson, USA). Fluorescent microscopy was
performed using a fluorescence microscope (Nikon,
Japan) with a B-2H filter cube.
RNA analysis
Total RNA was isolated using Trizol (Invitrogen, CA, USA)
and immobilised onto nylon membrane (Invitrogen, CA,
US) for detection using standard probe hybridisation. For
the detection of small antisense and sense RNAs encoded
by DualU6GFP, the following oligonucleotides were end-
labelled and hybridised to these membranes at 37°C for
1 h: 5'-TCG ACA AAA ACG GCA AGC TGA CCC TGA AGT
TTT T-3' or 5'-CTA GAA AAA CTT CAG GGT CAG CTT
GCC GTT TTT G-3'. For the detection of dEGFP mRNA,
the ORF of dEGFP was digested with HindIII and XbaI
from the vector pd4EGFP-N1 (Clontech, USA). For the
detection of 18S the following oligonucleotide 5'-
CTGCAGCAACTTTAATATACGCTATTGGAGCTGGAAT-
TACCAAAAAAAA-3' was used as a specific probe. For
these two sequences they were labelled using the Meg-
aprime kit (Amersham, USA). All hybridisations were per-
formed using ExpressHyb (Clontech, USA) according to
the manufacturer's instructions. Membranes were ana-
lysed using a phosphorimager (Molecular Dynamics,
USA) and an ImageQuant software package (Molecular
Dynamics, USA).
Western analysis
Cell lysates were prepared using RIPA buffer supple-
mented with protease inhibitors aprotonin (1 µg/ml), leu-
peptin (10 µg/ml) and DMSF (100 µg/ml). Total protein
was loaded onto 4–12% Bis-Tris agarose gels (Invitrogen,
CA, USA), separated by electrophoresis and transferred to
polyvinylidene fluoride (PVDF) membrane. The antibod-
ies used for detection of specific proteins included: GFP,
mouse polyclonal (Clontech), PKR monoclonal (Cell Sig-
naling), PKR phospho rabbit polyclonal (Cell Signaling),
p53 mouse monoclonal (Oncogene Research Products) or
β-actin mouse monoclonal (Sigma) antibodies. Second-
ary antibody detection was performed using either the
goat anti-mouse horseradish peroxidase (HRP)-linked or
the goat anti-rabbit HRP (SantaCruz), followed by visual-
isation using the luminol/enhancer chemiluminescent
substrate (Amersham Pharmacia Biotech, Piscataway, NJ).
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